Literature DB >> 9592022

Effects of tachykinin receptor antagonists on the rat jejunal distension pain response.

P G McLean1, R Garcia-Villar, J Fioramonti, L Buéno.   

Abstract

Distension of the rat intestine causes a cardiovascular response which is indicative of nociception. Since tachykinins are involved in nociception, we tested the effect of neurokinin receptor antagonists against the distension-induced response. The jejunal distension-induced depressor responses were inhibited in a dose-dependent fashion by CP 99,994 (+)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine, tachykinin NK1 receptor antagonist, ED50 = 0.8 mg/kg) and SR 48968 (S)-N-methyl-N[4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichloropheny l)butyl]benzamide, tachykinin NK2 receptor antagonist, ED50 = 0.7 mg/kg). SR 142801 (S)-(N)-(1-(3-(1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl)prop yl)-4-phenylpiperidin-4-yl)-N-methylacetamide, tachykinin NK3 receptor antagonist, 0.3-10 mg/kg) did not significantly affect the depressor responses to jejunal distension. In addition, CP 99,994 (3 mg/kg) and SR 48968 (3 and 10 mg/kg) reduced sensitivity to distension as revealed by a 2.7-fold (CP 99.994, 3 mg/kg), 2.6-fold (SR 48968, 3 mg/kg) and 4.7-fold (SR 48968, 10 mg/kg) increase in the threshold pressure. Intestinal compliance was not affected by the antagonists. In conclusion, these results suggest that tachykinin NK1 and NK2 but not NK3 receptors are possibly involved in the rat jejunal distension pain response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9592022     DOI: 10.1016/s0014-2999(98)00040-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Memory in the enteric nervous system.

Authors:  J B Furness; N Clerc; W A Kunze
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

2.  Nociception in persistent pancreatitis in rats: effects of morphine and neuropeptide alterations.

Authors:  Louis P Vera-Portocarrero; Ying Lu; Karin N Westlund
Journal:  Anesthesiology       Date:  2003-02       Impact factor: 7.892

3.  A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine.

Authors:  M Lördal; G Navalesi; E Theodorsson; C A Maggi; P M Hellström
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 4.  Visceral nociception.

Authors:  K N Westlund
Journal:  Curr Rev Pain       Date:  2000

5.  Development of colorectal sensitization is associated with increased eosinophils and mast cells in dextran sulfate sodium-treated rats.

Authors:  J M Tobin; L M D Delbridge; R Di Nicolantonio; P Bhathal
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

Review 6.  Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.

Authors:  Gareth J Sanger
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

Review 7.  Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome.

Authors:  Alessandro Lecci; Angela Capriati; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.